High-sensitivity C-reactive protein is an independent marker of abnormal coronary vasoreactivity in patients with non-obstructive coronary artery disease

American Heart Journal

Volumn 190, Issue , 2017, Pages 1-11

  Sara, Jaskanwal D S ^a   Prasad, Megha ^a   Zhang, Ming ^a   Lennon, Ryan J ^a   Herrmann, Joerg ^a   Lerman, Lilach O ^b   Lerman, Amir ^a  

^a Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ACETYLSALICYLIC ACID; ADENOSINE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH SENSITIVITY C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; NITRIC ACID DERIVATIVE; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ADULT; ARTERY DIAMETER; ARTICLE; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORONARY ANGIOGRAPHY; CORONARY ARTERY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CORONARY ENDOTHELIAL DYSFUNCTION; CORONARY VASOREACTIVITY; DIABETES MELLITUS; DIAGNOSTIC TEST ACCURACY STUDY; DRUG DOSE INCREASE; ENDOTHELIAL DYSFUNCTION; FEMALE; HEART CATHETERIZATION; HIGH RISK POPULATION; HUMAN; HYPERTENSION; LABORATORY; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PLASMA; PREDICTIVE VALUE; PRIORITY JOURNAL; THORAX PAIN; BLOOD; CORONARY BLOOD VESSEL; DIAGNOSTIC IMAGING; DOPPLER ECHOCARDIOGRAPHY; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; RETROSPECTIVE STUDY; RISK FACTOR; VASCULAR ENDOTHELIUM; VASODILATATION;

BIOMARKERS; C-REACTIVE PROTEIN; CARDIAC CATHETERIZATION; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY VESSELS; ECHOCARDIOGRAPHY, DOPPLER; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; VASODILATION;

EID: 85019382215     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2017.02.035     Document Type: Article

References (62)

1. 1. Bonetti, P.O., Lerman, L.O., Lerman, A., Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 23:2 (2003), 168–175.
2. 2. Reddy, K.G., Nair, R.N., Sheehan, H.M., et al. Evidence that selective endothelial dysfunction may occur in the absence of angiographic or ultrasound atherosclerosis in patients with risk factors for atherosclerosis. J Am Coll Cardiol 23:4 (1994), 833–843.
3. 3. Suwaidi, J.A., Hamasaki, S., Higano, S.T., et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 101:9 (2000), 948–954.
4. 4. Vita, J.A., Treasure, C.B., Nabel, E.G., et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 81:2 (1990), 491–497.
5. 5. Drexler, H., Zeiher, A.M., Meinzer, K., et al. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet 338:8782–8783 (1991), 1546–1550.
6. 6. Egashira, K., Inou, T., Hirooka, Y., et al. Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions. J Clin Invest 91:1 (1993), 29–37.
7. 7. Egashira, K., Inou, T., Hirooka, Y., et al. Evidence of impaired endothelium-dependent coronary vasodilatation in patients with angina pectoris and normal coronary angiograms. N Engl J Med 328:23 (1993), 1659–1664.
8. 8. Hasdai, D., Gibbons, R.J., Holmes, D.R. Jr., et al. Coronary endothelial dysfunction in humans is associated with myocardial perfusion defects. Circulation 96:10 (1997), 3390–3395.
9. 9. Quyyumi, A.A., Cannon, R.O. III, Panza, J.A., et al. Endothelial dysfunction in patients with chest pain and normal coronary arteries. Circulation 86:6 (1992), 1864–1871.
10. 10. Hasdai, D., Cannan, C.R., Mathew, V., et al. Evaluation of patients with minimally obstructive coronary artery disease and angina. Int J Cardiol 53:3 (1996), 203–208.
11. 11. Hasdai, D., Holmes, D.R. Jr., Higano, S.T., et al. Prevalence of coronary blood flow reserve abnormalities among patients with nonobstructive coronary artery disease and chest pain. Mayo Clin Proc 73:12 (1998), 1133–1140.
12. 12. Ludmer, P.L., Selwyn, A.P., Shook, T.L., et al. Paradoxical Vasoconstriction Induced by Acetylcholine in Atherosclerotic Coronary-Arteries. N Engl J Med 315:17 (1986), 1046–1051.
13. 13. Heistad, D.D., Armstrong, M.L., Marcus, M.L., et al. Augmented responses to vasoconstrictor stimuli in hypercholesterolemic and atherosclerotic monkeys. Circ Res 54:6 (1984), 711–718.
14. 14. Lopez, J.A., Armstrong, M.L., Piegors, D.J., et al. Effect of early and advanced atherosclerosis on vascular responses to serotonin, thromboxane A2, and ADP. Circulation 79:3 (1989), 698–705.
15. 15. Yoon, M.H., Reriani, M., Mario, G., et al. Long-term endothelin receptor antagonism attenuates coronary plaque progression in patients with early atherosclerosis. Int J Cardiol 168:2 (2013), 1316–1321.
16. 16. Lavi, S., Bae, J.H., Rihal, C.S., et al. Segmental coronary endothelial dysfunction in patients with minimal atherosclerosis is associated with necrotic core plaques. Heart 95:18 (2009), 1525–1530.
17. 17. Lerman, A., Zeiher, A.M., Endothelial function: cardiac events. Circulation 111:3 (2005), 363–368.
18. 18. Reriani, M.K., Flammer, A.J., Jama, A., et al. Novel functional risk factors for the prediction of cardiovascular events in vulnerable patients following acute coronary syndrome. Circ J 76:4 (2012), 778–783.
19. 19. Targonski, P.V., Bonetti, P.O., Pumper, G.M., et al. Coronary endothelial dysfunction is associated with an increased risk of cerebrovascular events. Circulation 107:22 (2003), 2805–2809.
20. 20. Libby, P., Ridker, P.M., Maseri, A., Inflammation and atherosclerosis. Circulation 105:9 (2002), 1135–1143.
21. 21. Choi, B.J., Matsuo, Y., Aoki, T., et al. Coronary endothelial dysfunction is associated with inflammation and vasa vasorum proliferation in patients with early atherosclerosis. Arterioscler Thromb Vasc Biol 34:11 (2014), 2473–2477.
22. 22. Lavi, S., McConnell, J.P., Rihal, C.S., et al. Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation 115:21 (2007), 2715–2721.
23. 23. Yang, E.H., McConnell, J.P., Lennon, R.J., et al. Lipoprotein-associated phospholipase A2 is an independent marker for coronary endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol 26:1 (2006), 106–111.
24. 24. Koenig, W., Sund, M., Frohlich, M., et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 99:2 (1999), 237–242.
25. 25. Ridker, P.M., Hennekens, C.H., Buring, J.E., et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342:12 (2000), 836–843.
26. 26. Kuller, L.H., Tracy, R.P., Shaten, J., et al. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 144:6 (1996), 537–547.
27. 27. Ridker, P.M., Cushman, M., Stampfer, M.J., et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336:14 (1997), 973–979.
28. 28. Tracy, R.P., Lemaitre, R.N., Psaty, B.M., et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol 17:6 (1997), 1121–1127.
29. 29. Ridker, P.M., Buring, J.E., Shih, J., et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98:8 (1998), 731–733.
30. 30. Roivainen, M., Viik-Kajander, M., Palosuo, T., et al. Infections, inflammation, and the risk of coronary heart disease. Circulation 101:3 (2000), 252–257.
31. 31. Haverkate, F., Thompson, S.G., Pyke, S.D., et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 349:9050 (1997), 462–466.
32. 32. Liuzzo, G., Biasucci, L.M., Gallimore, J.R., et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 331:7 (1994), 417–424.
33. 33. Morrow, D.A., Rifai, N., Antman, E.M., et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 31:7 (1998), 1460–1465.
34. 34. Biasucci, L.M., Liuzzo, G., Grillo, R.L., et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 99:7 (1999), 855–860.
35. 35. Ridker, P.M., Rifai, N., Pfeffer, M.A., et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 98:9 (1998), 839–844.
36. 36. Yudkin, J.S., Stehouwer, C.D., Emeis, J.J., et al. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?. Arterioscler Thromb Vasc Biol 19:4 (1999), 972–978.
37. 37. Schalkwijk, C.G., Poland, D.C., van Dijk, W., et al. Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia 42:3 (1999), 351–357.
38. 38. Cleland, S.J., Sattar, N., Petrie, J.R., et al. Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clin Sci (Lond) 98:5 (2000), 531–535.
39. 39. Fichtlscherer, S., Rosenberger, G., Walter, D.H., et al. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 102:9 (2000), 1000–1006.
40. 40. Osto, E., Coppolino, G., Volpe, M., et al. Restoring the dysfunctional endothelium. Curr Pharm Des 13:10 (2007), 1053–1068.
41. 41. Widmer, R.J., Flammer, A.J., Herrmann, J., et al. Circulating humanin levels are associated with preserved coronary endothelial function. Am J Physiol Heart Circ Physiol 304:3 (2013), H393–H397.
42. 42. Lerman, A., Holmes, D.R. Jr., Bell, M.R., et al. Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans. Circulation 92:9 (1995), 2426–2431.
43. 43. Bell, M.R., Britson, P.J., Chu, A., et al. Validation of a new UNIX-based quantitative coronary angiographic system for the measurement of coronary artery lesions. Catheter Cardiovasc Diagn 40:1 (1997), 66–74.
44. 44. Bove, A.A., Holmes, D.R. Jr., Owen, R.M., et al. Estimation of the effects of angioplasty on coronary stenosis using quantitative video angiography. Catheter Cardiovasc Diagn 11:1 (1985), 5–16.
45. 45. Hori, M., Kitakaze, M., Adenosine, the heart, and coronary circulation. Hypertension 18:5 (1991), 565–574.
46. 46. Wei, J., Mehta, P.K., Johnson, B.D., et al. Safety of coronary reactivity testing in women with no obstructive coronary artery disease: results from the NHLBI-sponsored WISE (Women's Ischemia Syndrome Evaluation) study. JACC Cardiovasc Interv 5:6 (2012), 646–653.
47. 47. Serruys, P.W., di Mario, C., Piek, J., et al. Prognostic value of intracoronary flow velocity and diameter stenosis in assessing the short- and long-term outcomes of coronary balloon angioplasty: the DEBATE Study (Doppler Endpoints Balloon Angioplasty Trial Europe). Circulation 96:10 (1997), 3369–3377.
48. 48. Flammer, A.J., Anderson, T., Celermajer, D.S., et al. The assessment of endothelial function: from research into clinical practice. Circulation 126:6 (2012), 753–767.
49. 49. Maniu, C.V., Higano, S.T., Lerman, A., Assessing coronary endothelial dysfunction. Circulation, 106(11), 2002, e48 [discussion e48].
50. 50. Prasad, M., Reriani, M., Khosla, S., et al. Coronary microvascular endothelial dysfunction is an independent predictor of development of osteoporosis in postmenopausal women. Vasc Health Risk Manag 10 (2014), 533–538.
51. 51. Yeh, E.T., Willerson, J.T., Coming of age of C-reactive protein: using inflammation markers in cardiology. Circulation 107:3 (2003), 370–371.
52. 52. Ridker, P.M., Buring, J.E., Cook, N.R., et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 107:3 (2003), 391–397.
53. 53. Ridker, P.M., Rifai, N., Clearfield, M., et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344:26 (2001), 1959–1965.
54. 54. Verma, S., Kuliszewski, M.A., Li, S.H., et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 109:17 (2004), 2058–2067.
55. 55. Yang, M., Chu, E.M., Caslake, M.J., et al. Lipoprotein-associated phospholipase A2 decreases oxidized lipoprotein cellular association by human macrophages and hepatocytes. Biochim Biophys Acta 1801:2 (2010), 176–182.
56. 56. Ridker, P.M., Rifai, N., Rose, L., et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347:20 (2002), 1557–1565.
57. 57. Venugopal, S.K., Devaraj, S., Yuhanna, I., et al. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 106:12 (2002), 1439–1441.
58. 58. Verma, S., Wang, C.H., Li, S.H., et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 106:8 (2002), 913–919.
59. 59. Clapp, B.R., Hirschfield, G.M., Storry, C., et al. Inflammation and endothelial function: direct vascular effects of human C-reactive protein on nitric oxide bioavailability. Circulation 111:12 (2005), 1530–1536.
60. 60. Venugopal, S.K., Devaraj, S., Jialal, I., C-reactive protein decreases prostacyclin release from human aortic endothelial cells. Circulation 108:14 (2003), 1676–1678.
61. 61. Verma, S., Li, S.H., Badiwala, M.V., et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 105:16 (2002), 1890–1896.
62. 62. Ridker, P.M., Glynn, R.J., Hennekens, C.H., C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 97:20 (1998), 2007–2011.